Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a report released on Monday.

Several other brokerages have also recently issued reports on VYGR. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Wedbush dropped their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Stock Down 4.5 %

Shares of NASDAQ VYGR opened at $5.39 on Monday. The business’s 50 day moving average is $6.62 and its two-hundred day moving average is $7.49. Voyager Therapeutics has a 52-week low of $5.38 and a 52-week high of $11.72. The firm has a market cap of $294.18 million, a price-to-earnings ratio of 7.58 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the business earned ($0.59) EPS. Analysts anticipate that Voyager Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.53% of the stock is owned by insiders.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after acquiring an additional 702,030 shares during the period. Great Point Partners LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter valued at $12,668,000. Armistice Capital LLC boosted its stake in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the period. Price T Rowe Associates Inc. MD grew its position in Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after purchasing an additional 37,144 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC purchased a new position in Voyager Therapeutics during the 2nd quarter worth $1,012,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.